Charles L. Loprinzi, MD, on Olanzapine for Prevention of CINV
2015 Palliative Care in Oncology Symposium
Charles L. Loprinzi, MD, of the Mayo Clinic, discusses olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy (Abstract 176).
Diane Portman, MD
Diane Portman, MD, of Moffitt Cancer Center, discusses clinical pathways that embed palliative care along the spectrum of care for a variety of cancer disease states.
Vicki Jackson, MD, MPH
Vicki Jackson, MD, MPH, of Massachusetts General Hospital, summarizes her keynote lecture (plenary talk).
Lawrence H. Einhorn, MD
Lawrence H. Einhorn, MD, of Indiana University Simon Cancer Center, discusses the encouraging study findings on olanzapine for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy (Abstract 176).
Betty Ferrell, PhD, RN
Betty Ferrell, PhD, RN, of City of Hope, discusses two papers that look at an important issue from different perspectives: depression and anxiety among family caregivers of patients with advanced cancer, and the link between oncologists’ dispositional affect and depressive symptoms in their patients with metastatic cancer (Abstracts 224, 214).
Lawrence H. Einhorn, MD
Lawrence H. Einhorn, MD, of Indiana University Simon Cancer Center, discusses the ways in which a dedicated palliative radiation consult service can improve the quality of palliative cancer care (Abstract 110).